Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 5/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25156216 | 1.00 | CHRNA3 (0.54) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL25155254 | 0.89 | CHRNA3 (0.55) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL25155553 | 0.89 | CHRNA3 (0.55) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL25155420 | 0.89 | CHRNA3 (0.55) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL25155353 | 0.86 | CHRNA3 (0.53) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL25156206 | 0.86 | CHRNA3 (0.53) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL25155475 | 0.86 | CHRNA3 (0.53) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL7817923 | 0.81 | CHRNA3 (0.50) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL31212859 | 0.81 | CHRNB4 (0.58) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL31212916 | 0.81 | CHRNB4 (0.58) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024215817-A1 | NOVEL 5-CYCLOPROYLQUINOLINE DERIVATIVES AS PLPRO INHIBITORS | PFIZER INC. (US) | 2024-10-17 | — | — | WO | claimed |
| US-20260085063-A1 | BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | UNIV RUTGERS (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2024215817-A1 | NOVEL 5-CYCLOPROYLQUINOLINE DERIVATIVES AS PLPRO INHIBITORS | PFIZER INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085063-A1 | BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ACE2, CTRL, CTSL | CHRNA3 3841/4885CHRNB4 3949/4885CHRNB2 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.